SUPERNUS PHARMACEUTICALS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $4.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $2.20M, a 63.88% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $2.26M, a 68.38% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $1.34M.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $1.34M.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $7.98M, a 46.37% increase from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $5.45M, a 16.16% decline from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $6.50M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $4.45M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $2.26M 10-Q · filed 2026-05-05 | ||
| 2025-12-31 | $7.98M 10-K · filed 2026-03-02 | ||
| 2025-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $2.68M 10-Q · filed 2026-08-03 | |
| 2025-03-31 | $1.34M 10-Q · filed 2026-05-05 | ||
| 2024-12-31 | $5.45M 10-K · filed 2026-03-02 | ||
| 2023-12-31 | $6.50M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |